Vitality Watch

Dossier pubmed preclinical 15-apr-2026
Animal model, organoid, or cell-culture result — not yet human

Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.

Key claim: Tubeimoside I selectively kills senescent cells by targeting ATP1A1 and disrupting potassium/ion homeostasis, improving motor function and reducing senescence markers in aged mouse models without clear toxicity.

Abstract

BACKGROUND: Senescent cells accumulate with age and contribute to age-related diseases, which makes their selective elimination a promising strategy for therapeutic intervention. Tubeimoside I (TBMS1), a natural triterpenoid saponin derived from Bolbostemma paniculatum, has been extensively studied for its anticancer properties. However, its potential role as a senolytics has yet to be determined. PURPOSE: This study elucidates the anti-aging effects and underlying mechanism of TBMS1 in vivo and in vitro. METHODS: The anti-aging effects of TBMS1 were evaluated both in vitro and in vivo using CCK-8, senescence-associated β-galactosidase staining, immunofluorescence, flow cytometry, immunohistochemistry, and western blotting. Furthermore, its potential targets and underlying mechanism were investigated through thermal proteome profiling and comprehensive whole-proteome analysis. RESULTS: We identified that TBMS1 is a senolytic agent. We identified that TBMS1 specifically targeted sodium/potassium-ATPase alpha 1 subunit (ATP1A1), a protein involved in maintaining ion homeostasis, which was highly expressed in senescent cells. TBMS1 modulated ATP1A1 activity, leading to altered intracellular potassium dynamics and disruption of ion homeostasis, which contributed to mitochondrial dysfunction and apoptosis in senescent cells. In vivo, TBMS1 improved motor function, reduced senescence markers, and alleviated tissue damage in both radiation-induced and naturally aged mouse models, without significant toxicity observed. CONCLUSION: These findings position TBMS1 as a promising and mechanistically distinct senolytic candidate, offering new insights into ion homeostasis modulation as a therapeutic strategy for aging and senescence-related disorders.

Why this matters

Most preclinical senolytics converge on BCL-2 family or tyrosine-kinase survival pathways; Tubeimoside I nominates the Na+/K±ATPase α1 subunit and ion-homeostasis collapse as a distinct vulnerability enriched in senescent cells, broadening the mechanistic map of what makes ‘zombie cells’ druggable. The finding sits firmly in the mouse-model tier — selectivity, dosing window, and off-target ATP1A1 effects (cardiac, neural) all remain to be characterized before any human-translation narrative is warranted.

Source

Link

Briefing card

Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities.
Stage: preclinical · pubmed · 15-apr-2026

Tubeimoside I selectively kills senescent cells by targeting ATP1A1 and disrupting potassium/ion homeostasis, improving motor function and reducing senescence markers in aged mouse models without clear toxicity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.phymed.2026.158202

build build 880 · 2bcef25 · 2026-11-18